Treatment Patterns, Adherence, Persistence, and Healthcare Resource Utilization in Acromegaly: A Real-World Analysis

Archive ouverte

Fleseriu, Maria | Barkan, Ariel | Brue, Thierry | Duquesne, Edouard | Houchard, Aude | del Pilar Schneider, Maria | Ribeiro-Oliveira, Antonio | Melmed, Shlomo

Edité par CCSD ; Oxford University Press -

International audience. Treatment of acromegaly is multimodal for many patients, and medical treatments include somatostatin receptor ligands (SRLs), dopamine agonists (DAs), and growth hormone receptor antagonists (GHRAs). However, recent real-world evidence on treatment patterns for patients with acromegaly is limited. This study evaluated medication usage, treatment changes, adherence, persistence, comorbidities, and healthcare resource utilization, using de-identified data from MarketScan®, a US claims database. Eligible patients (n = 882) were those receiving monotherapy or combination therapy for ≥90 days without treatment gaps. Mean age at diagnosis was 48.6 years; 50.1% of patients were female. Over half (59.4%) had one line of treatment (LOT); 23.1% had two LOTs; 17.5% had at least three LOTs. Most patients (94.6%) initiated treatment with monotherapies. The most common first-line monotherapy treatments were cabergoline (DA, 36.8%), octreotide long-acting release (first-generation SRL, 29.5%), and lanreotide depot (first-generation SRL, 22.5%). Adherence for first-line treatments (proportion of days covered), was higher for first-generation SRLs (lanreotide depot: 0.8), compared with DAs (0.7). Treatment persistence (time between the first treatment record and a change in LOT/censoring) in LOT 1 was higher for GHRAs (24.8 months) and first-generation SRLs (20.0 months), compared with DAs (14.4 months). Female patients and those diagnosed at a younger age were more likely to have shorter treatment persistence. The most prevalent comorbidities were hyperlipidemia, essential hypertension, and sleep apnea. Patients with more comorbidities had more healthcare visits during the first year after diagnosis, suggesting increased disease burden. Real-world evidence on treatment patterns provides insights into recommendations for individualized therapy.

Suggestions

Du même auteur

Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

Archive ouverte | Ho, Ken | CCSD

International audience. Abstract The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with ...

International Multicenter Validation Study of the SAGIT® Instrument in Acromegaly

Archive ouverte | Giustina, Andrea | CCSD

International audience. Abstract Context The SAGIT® instrument (SAGIT) has been developed to enable accurate characterization of acromegaly disease activity. Objective We evaluated the ability of SAGIT to discrimina...

Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence Reply

Archive ouverte | Fleseriu, Maria | CCSD

International audience

Chargement des enrichissements...